MBL Wealth LLC cut its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 5.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,636 shares of the biopharmaceutical company’s stock after selling 701 shares during the quarter. MBL Wealth LLC’s holdings in Pfizer were worth $475,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of PFE. Lam Group Inc. acquired a new position in Pfizer during the fourth quarter worth $25,000. Worth Asset Management LLC purchased a new stake in Pfizer during the first quarter worth $29,000. My Personal CFO LLC purchased a new stake in Pfizer during the fourth quarter worth $32,000. Mendota Financial Group LLC purchased a new stake in Pfizer during the fourth quarter worth $33,000. Finally, Freedom Wealth Alliance LLC purchased a new stake in Pfizer during the fourth quarter worth $35,000. 67.80% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several analysts have recently issued reports on the company. Barclays reduced their price objective on Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Daiwa Capital Markets downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price objective on the stock. in a research report on Thursday, May 11th. JPMorgan Chase & Co. set a $45.00 price objective on Pfizer in a research report on Monday, February 27th. StockNews.com started coverage on Pfizer in a research report on Thursday, May 18th. They set a “buy” rating on the stock. Finally, Morgan Stanley reduced their target price on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, April 10th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $47.33.
Insider Activity
Pfizer Stock Performance
Shares of NYSE:PFE opened at $38.73 on Friday. The firm has a market capitalization of $218.64 billion, a PE ratio of 7.62, a P/E/G ratio of 1.33 and a beta of 0.64. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.37 and a quick ratio of 1.11. The business has a 50-day moving average of $38.77 and a two-hundred day moving average of $42.81. Pfizer Inc. has a 12 month low of $36.17 and a 12 month high of $54.93.
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.00 by $0.23. Pfizer had a return on equity of 37.53% and a net margin of 31.25%. The company had revenue of $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. During the same period in the prior year, the firm posted $1.62 earnings per share. The firm’s revenue was down 28.8% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 3.35 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.23%. Pfizer’s dividend payout ratio (DPR) is currently 32.28%.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Get a free research report on Pfizer from StockNews.com
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Darden Restaurants: Ring The Register Or Time To Buy?
- United Airlines: Cleared For Takeoff As It Approaches Buy Point?
- KB Home Hits Peak: Pullback Imminent
- Five stocks we like better than Pfizer
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
